<DOC>
	<DOCNO>NCT01069289</DOCNO>
	<brief_summary>The primary purpose study investigate Symbicort effective Oxis increase forced expiratory volume one second ( FEV1 ) , measure clinic , patient COPD .</brief_summary>
	<brief_title>Efficacy Safety Study Symbicort速 Turbuhaler速 Versus Oxis速 Turbuhaler速 Chronic Obstructive Pulmonary Disease ( COPD ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>A current clinical diagnosis Chronic Obstructive Pulmonary Disease Documented Chronic Obstructive Pulmonary Disease symptoms 2 year A smoking history least 10 pack year History and/or current clinical diagnosis asthma History and/or current clinical diagnosis atopic diseases allergic rhinitis</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Symbicort</keyword>
	<keyword>Oxis</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>COPD</keyword>
	<keyword>Efficacy</keyword>
</DOC>